US FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older

–  Empagliflozin is the first and only SGLT2 inhibitor approved for this patient population–  More than 5,700 young people are diagnosed with type 2 diabetes annually in the U.S. RIDGEFIELD, Conn. and INDIANAPOLIS, June 21, 2023 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg and 25 mg tablets … Read more

Lilly to present new research in the treatment of diabetes and obesity at the American Diabetes Association’s® 83rd Scientific Sessions

Full SURMOUNT-2 phase 3 data on the efficacy and safety of tirzepatide for chronic weight management in adults with obesity or overweight and type 2 diabetes New phase 2 data for retatrutide and orforglipron showcase promise of Lilly’s pipeline and commitment to transform diabetes and obesity care INDIANAPOLIS, June 20, 2023 /PRNewswire/ — Eli Lilly … Read more

First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention

Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint Emgality performed numerically better than the active comparator on key secondary endpoints of the CHALLENGE-MIG trial The CHALLENGE-MIG study demonstrates Lilly’s commitment to migraine research and results underscore that people living … Read more

Lilly ESG Report Highlights Progress Towards Sustainability Goals

Reduced greenhouse gas emissions by 20% Improved access to Lilly insulins in the U.S. Nearly doubled patients reached in resource-limited settings through global health efforts INDIANAPOLIS, May 22, 2023 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today released its latest Environmental, Social and Governance (ESG) report showing progress towards the company’s ambitious sustainability goals, … Read more